<DOC>
	<DOCNO>NCT01946646</DOCNO>
	<brief_summary>The purpose study determine whether combination TS-1 concurrent short-course radiotherapy feasible metastatic pancreatic cancer . The rationale study primarily base good efficacy gemcitabine plus TS-1 great potential local control concurrent chemoradiotherapy pancreatic cancer .</brief_summary>
	<brief_title>Phase I Study TS-1 With Concurrent Radiotherapy Treat Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>histologically cytologically proven , newly diagnose pancreatic adenocarcinoma adenosquamous carcinoma previous radiotherapy , chemotherapy , target therapy , curative surgery , immunotherapy use pancreatic cancer presence least one measurable lesion , must meet criterion ≥ 20 mm least one dimension conventional CT/MRI ≥ 10 mm spiral CT scan age 20 79 year registration ECOG PS 0 1 adequate major organ function ability take oral study medication ( TS1 ) clinically significant abnormal ECG finding within 28 day ( 4 week ) prior registration voluntarily sign write informed consent form pulmonary fibrosis interstitial pneumonitis diagnose within 28 day prior registration presence diarrhea ≥ CTCAE v.4.03 grade 2 concomitant active infection significant comorbid medical condition moderate severe ascites pleural effusion require drainage central nervous system metastasis prior concurrent malignancy within last 3 year concomitant treatment flucytosine , phenytoin warfarin pregnant woman nurse mother , positive pregnancy test severe mental disorder judge ineligible physician participation study due safety concern</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>